|
|
| (2 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of the trimerization domain of human EML4== | | ==Crystal structure of the trimerization domain of human EML4== |
| - | <StructureSection load='4cgc' size='340' side='right' caption='[[4cgc]], [[Resolution|resolution]] 2.90Å' scene=''> | + | <StructureSection load='4cgc' size='340' side='right'caption='[[4cgc]], [[Resolution|resolution]] 2.90Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4cgc]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CGC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CGC FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4cgc]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CGC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4CGC FirstGlance]. <br> |
| - | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=MSE:SELENOMETHIONINE'>MSE</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.901Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4cgb|4cgb]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MSE:SELENOMETHIONINE'>MSE</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4cgc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cgc OCA], [http://pdbe.org/4cgc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4cgc RCSB], [http://www.ebi.ac.uk/pdbsum/4cgc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4cgc ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4cgc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cgc OCA], [https://pdbe.org/4cgc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4cgc RCSB], [https://www.ebi.ac.uk/pdbsum/4cgc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4cgc ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[http://www.uniprot.org/uniprot/EMAL4_HUMAN EMAL4_HUMAN]] Selection of therapeutic option in non-small cell lung carcinoma. | + | [https://www.uniprot.org/uniprot/EMAL4_HUMAN EMAL4_HUMAN] Selection of therapeutic option in non-small cell lung carcinoma. |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/EMAL4_HUMAN EMAL4_HUMAN]] May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic. | + | [https://www.uniprot.org/uniprot/EMAL4_HUMAN EMAL4_HUMAN] May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 25: |
Line 25: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Bayliss, R]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Richards, M W]] | + | [[Category: Large Structures]] |
| - | [[Category: Cell cycle]] | + | [[Category: Bayliss R]] |
| - | [[Category: Coiled-coil]] | + | [[Category: Richards MW]] |
| - | [[Category: Eml4-alk]]
| + | |
| - | [[Category: Nsclc]]
| + | |
| Structural highlights
Disease
EMAL4_HUMAN Selection of therapeutic option in non-small cell lung carcinoma.
Function
EMAL4_HUMAN May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic.
Publication Abstract from PubMed
Proteins of the echinoderm microtubule associated protein-like (EML) family contribute to formation of the mitotic spindle and interphase microtubule (MT) network. EML1-4 consist of WD40 repeats and an N-terminal region containing a putative coiled-coil. Recurrent gene rearrangements in non-small cell lung cancer (NSCLC) fuse EML4 to anaplastic lymphoma kinase (ALK) causing expression of several oncogenic fusion variants. The fusions have constitutive ALK activity due to self-association through the EML4 coiled-coil. We have determined crystal structures of the coiled-coils from EML2 and EML4, which describe the structural basis of both EML self-association and oncogenic EML4-ALK activation. The structures reveal a trimeric oligomerization state directed by a conserved pattern of hydrophobic residues and salt bridges. We show that the trimerization domain (TD) of EML1 is necessary and sufficient for self-association. The TD is also essential for MT binding, however this property requires an adjacent basic region. These observations prompted us to investigate MT association of EML4-ALK and EML1-ABL1 fusions in which variable portions of the EML component are present. Uniquely, EML4-ALK variant 3, which includes the TD and basic region of EML4 but none of the WD40 repeats, was localized to MTs, both when expressed recombinantly and in a patient-derived NSCLC cell line (H2228). This raises the question of whether the mislocalization of ALK activity to MTs might influence downstream signalling and malignant properties of cells. Furthermore, the structure of EML4 TD may enable the development of protein-protein interaction inhibitors targeting the trimerization interface, providing a possible avenue towards therapeutic intervention in EML4-ALK NSCLC.
Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.,Richards MW, O'Regan L, Roth D, Montgomery JM, Straube A, Fry AM, Bayliss R Biochem J. 2015 Mar 5. PMID:25740311[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Richards MW, O'Regan L, Roth D, Montgomery JM, Straube A, Fry AM, Bayliss R. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. Biochem J. 2015 Mar 5. PMID:25740311 doi:http://dx.doi.org/10.1042/BJ20150039
|
